Clinical characteristics, treatment patterns and adherence in patients with asthma on multiple inhaler triple therapy: a review of findings

References

• Cazzola M, Puxeddu E, Matera MG, et al. A potential role of triple therapy for asthma patients. Expert Rev Respir Med. 2019;13(11):1079–1085.
   PubMed Web of Science ®Google Scholar
• Matera MG, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev. 2020;72(1):218–252.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Facciolo F, et al. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: synergy of triple combination therapy on human airway smooth muscle ex vivo. Br J Pharmacol. 2020;177(5):1150–1163.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737–1749.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000–1012.
   PubMed Web of Science ®Google Scholar
• Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, phase IIIb, non-inferiority study (ARGON). Respir Med. 2020;170:106021.
   PubMed Web of Science ®Google Scholar
• Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9(1):69–84.
   PubMed Web of Science ®Google Scholar
• Spain CV, Dayal P, Ding Y, et al. Usage of long-acting muscarinic antagonists and biologics as add-on therapy for patients in the United States with moderate-to-severe asthma. J Asthma. 2022;59(6):1237–1247.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Nakano T, Fukuyama S, et al. Effects of tiotropium on lung function in severe asthmatics with or without emphysematous changes. Pulm Pharmacol Ther. 2013;26(2):159–166.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Moroni-Zentgraf P, Tashkin DP, et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med. 2016;117:198–206.
   PubMed Web of Science ®Google Scholar
• Khurana S, Paggiaro P, Buhl R, et al. Tiotropium reduces airflow obstruction in asthma patients, independent of body mass index. J Allergy Clin Immunol Pract. 2019;7(7):2425–2428.
   PubMed Web of Science ®Google Scholar
• Doherty DE, Bleecker ER, Moroni-Zentgraf P, et al. Tiotropium Respimat efficacy and safety in asthma: relationship to age. J Allergy Clin Immunol Pract. 2020;8(8):2653–2660.
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Calzetta L, et al. Triple combination inhalers in chronic obstructive pulmonary disease and asthma. US Respiratory & Pulmonary Diseases. 2020;5(1):18–33.
   Google Scholar
• Cloutier MM, Baptist AP, Blake KV, et al., 2020 focused updates to the asthma management guidelines: a report from the national asthma education and prevention program coordinating committee expert panel working group. J Allergy Clin Immunol. 2020;146(6):1217–1270.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Bacharier LB, Bateman ED, et al., Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2021;59(1):2102730.
   PubMed Web of Science ®Google Scholar
• Matera MG, Belardo C, Rinaldi M, et al. New perspectives on the role of muscarinic antagonists in asthma therapy. Expert Rev Respir Med. 2020;14(8):817–824.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Matera MG. Long-acting muscarinic antagonists and small airways in asthma: which link? Allergy. 2021;76(7):1990–2001.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Braido F, Calzetta L, et al. The 5T approach in asthma: triple therapy targeting treatable traits. Respir Med. 2022;200:106915.
   PubMed Web of Science ®Google Scholar
• Lang DM, Davis RS. The long-acting beta-agonist controversy: a clinical dilemma. Allergy Asthma Proc. 2007;28(2):136–144.
   Web of Science ®Google Scholar
• Cazzola M, Segreti A, Bettoncelli G, et al. Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. Prim Care Respir J. 2011;20(3):291–298.
   PubMedGoogle Scholar
• Abadoglu O, Berk S. Tiotropium may improve asthma symptoms and lung function in asthmatic patients with irreversible airway obstruction: the real-life data. Clin Respir J. 2016;10(4):421–427.
   PubMed Web of Science ®Google Scholar
• Baan EJ, Hoeve CE, De Ridder M, et al. The ALPACA study: (In)Appropriate LAMA prescribing in asthma: a cohort analysis. Pulm Pharmacol Ther. 2021;71:102074.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Fairburn-Beech J, Sato K, et al., Clinical characteristics, treatment patterns, disease burden, and persistence/adherence in patients with asthma initiating inhaled triple therapy: real-world evidence from Japan. Curr Med Res Opin. 2020;36(6):1049–1057.
   PubMed Web of Science ®Google Scholar
• Oppenheimer J, Bogart M, Bengtson LGS, et al., Treatment patterns and disease burden associated with multiple-inhaler triple-therapy use in asthma. J Allergy Clin Immunol Pract. 2022;10(2):485–494.
   PubMed Web of Science ®Google Scholar
• Barrecheguren M, Monteagudo M, Miravitlles M, et al., Characteristics and treatment patterns of patients with asthma on multiple-inhaler triple therapy in Spain. NPJ Prim Care Respir Med. 2022;32(1):11.
   PubMed Web of Science ®Google Scholar
• Agusti A, Fabbri L, Lahousse L, et al., Single inhaler triple therapy (SITT) in asthma: systematic review and practice implications. Allergy. 2022;77(4):1105–1113.
   PubMed Web of Science ®Google Scholar
• Meeraus W, Zhang S, Fowler A, et al. Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study. Eur Respir J. 2020;56:2277.
   Web of Science ®Google Scholar
• Meeraus W, Liu Y, Numbere B, et al. Discontinuation and re-initiation of multiple inhaler triple therapy in adult patients with asthma: a cohort study. Chest. 2021;160(4,Suppl):A1958–A1959.
   Web of Science ®Google Scholar
• Delea TE, Hagiwara M, Stanford RH, et al. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma. Clin Ther. 2008;30(3):560–571.
   PubMed Web of Science ®Google Scholar
• Busse WW, Abbott CB, Germain G, et al.Adherence and persistence to single-inhaler versus multiple-inhaler triple therapy for asthma management. J Allergy Clin Immunol Pract. 2022;10(11):2904–2913.e6.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ora J, Rogliani P, et al. Role of muscarinic antagonists in asthma therapy. Expert Rev Respir Med. 2017;11(3):239–253.
   PubMed Web of Science ®Google Scholar
• Willson J, Bateman ED, Pavord I, et al. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists. Appl Health Econ Health Policy. 2014;12(4):447–459.
   PubMedGoogle Scholar
• Hong SH, Cho JY, Kim TB, et al. Cost-effectiveness of tiotropium in elderly patients with severe asthma using real-world data. J Allergy Clin Immunol Pract. 2021;9(5):1939–1947.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Matera MG. The latest on the role of LAMAs in asthma. J Allergy Clin Immunol. 2020;146(6):1288–1291.
   PubMed Web of Science ®Google Scholar
• Mansfield L, Bernstein JA. Tiotropium in asthma: from bench to bedside. Respir Med. 2019;154:47–55.
   PubMed Web of Science ®Google Scholar
• Huang J, Pansare M. New treatments for asthma. Immunol Allergy Clin North Am. 2021;41(4):555–569.
   PubMed Web of Science ®Google Scholar
• Averell CM, Laliberté F, Duh MS, et al. Characterizing real-world use of tiotropium in asthma in the USA. J Asthma Allergy. 2019;12:309–321.
   PubMed Web of Science ®Google Scholar
• Gon Y, Ohyanagi N, Kobayashi A. The association between control level and self-reported treatment adherence across different treatment types in Japanese asthma patients. Respir Investig. 2021;59(4):454–463.
   PubMed Web of Science ®Google Scholar
• Mtibaa M, Gupta S, Muthukumar M, et al. Cost-effectiveness of once-daily, single-inhaler indacaterol acetate/glycopyrronium bromide/mometasone furoate in patients with uncontrolled moderate-to-severe asthma in Canada. Clinicoecon Outcomes Res. 2021;13:957–967.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Naviglio S, et al. An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. Expert Opin Pharmacother. 2022;23(10):1205–1216.
   PubMed Web of Science ®Google Scholar
• Ding B, Small M, Scheffel G, et al. . Maintenance inhaler preference, attribute importance, and satisfaction in prescribing physicians and patients with asthma, COPD, or asthma–COPD overlap syndrome consulting for routine care. Int J Chron Obstruct Pulmon Dis. 2018;13:927–936.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Bianco A, Blasi F, et al. What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis. Respir Med. 2020;166:105937.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG, Rogliani P, et al. Step-up and step-down approaches in the treatment of asthma. Expert Rev Respir Med. 2021;15(9):1159–1168.
   PubMed Web of Science ®Google Scholar
• Rank MA, Johnson R, Branda M, et al. Long-term outcomes after stepping down asthma controller medications: a claims-based, time-to-event analysis. Chest. 2015;148(3):630–639.
   PubMed Web of Science ®Google Scholar